ABSTRACT
Tecnologías evaluadas: Nueva: anticuerpos antipéptidos cíclicos citrulinados; Actual: Factor reumatoide. Población: Pacientes mayores de 16 años con artritis reumatoide en Colombia. Perspectiva: La perspectiva del presente AIP corresponde al tercero pagador, que en este caso es el Sistema General de Seguridad Social en Salud (SGSSS) en Colombia. Horizonte temporal: El horizonte temporal de este AIP en el caso base corresponde a un año. Adicionalmente se reportan las estimaciones del impacto presupuestal para los años 2 y 3, bajo el supuesto de la inclusión en el POS en el año 1. Costos incluidos: Costos de las tecnologías analizadas. Fuente de costos: Los precios de cada tecnología considerada fueron\r\nconsultados en el manual tarifario ISS 2001 y ajustados con un +25%, +30% y +48%. Los precios de las consultas médicas fueron consultados en el manual tarifario ISS 2001 y ajustados con un +30%. Escenarios: \r\nEn tanto el escenario 1 como el escenario 2 se asume que la adopción de las nuevas tecnologías resultará en que su participación de mercado equilibraría debido a la preferencia de los clínicos de utilizar la combinación de tanto la tecnología actual con la tecnología nueva. Resultados: Se necesitaría una inversión de $11.136.331.800,00 para el año 1, $12.624.171.516,00 para el año 2 y 14.436.417.841,56 para el año 3 para la inclusión de la prueba anti-CCP en el POS para pacientes con artritis reumatoide mayores de 16 años en Colombia, bajo el presupuesto que la adopción de la nueva tecnología llevaría a un cambio en la participación del mercado.(AU)
Subject(s)
Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Peptides, Cyclic/analysis , Arthritis, Rheumatoid/diagnosis , Citrulline/analysis , Antibodies/blood , Colombia , Costs and Cost Analysis/methods , Biomedical TechnologyABSTRACT
To detect serum and synovial fluid anti-CCP antibodies in psoriatic arthritis patients [PsA] as compared to rheumatoid arthritis [RA] and psoriasis [Ps] patients. Anti-CCP antibodies and rheumatoid factor [RF] were measured in the serum of 30 patients with RF negative PsA, 30 patients with RA, 30 patients with Ps and 20 sex and age matched healthy controls. Synovial fluid anti-CCP antibodies were also measured in 10 patients with PsA and 12 RA patients having synovitis and knee effusion. Two out of thirty patients [6.66%] with PsA, 28/30 [93%] with RA, none [0%] of patients with psoriasis without arthritis, or healthy controls had serum anti-CCP antibodies above the cut off level. All patients with PsA with positive anti-CCP antibodies had polyarthritis. Anti-CCP Abs were detected in the synovial fluid in 1/10 [10%] of patients with PsA with knee effusion and in 11/12 [91.6%] of patients with RA with knee effusions. RF was positive in 85% of RA patients and negative in all patients with PsA. Anti-CCP antibodies may be present in patients with psoriatic arthritis in both serum and synovial fluid. Patients with psoriatic arthritis positive for anti-CCP antibodies more often had poly articular disease, more severe disease and erosive changes. Anti-CCP antibodies in both serum and synovial fluid were more prevalent in patients with rheumatoid arthritis than in patients with psoriatic arthritis while it was negative in serum of patients with psoriasis without arthritis
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Peptides, Cyclic/analysis , Synovial Fluid , Arthritis, Psoriatic/blood , Antibodies/blood , Antibodies/analysisABSTRACT
TBX21 (T-bet) is a member of the T-box family of transcriptional factors that contain a conserved DNA binding domain. TBX21 is a critical regulator of the commitment to the Th1 lineage and IFN-gamma production. Th1 and Th2 cells cross-regulate the differentiation of each other, and in this way TBX21 could be an attractive candidate gene for treating autoimmune disease such as rheumatoid arthritis (RA). In present study, we analyzed the genotypic frequencies of six polymorphisms of the TBX21 gene between the 367 RA patients and the 572 healthy controls. We showed that the g.-1514T>C and c.99C>G polymorphisms are suggestively associated with RA susceptibility. It is interesting that the genotypic frequencies of the TBX21 polymorphisms (g.-1514T>C and c.2103A>C) in the male RA patients were significantly different from the male control group (P = 0.0016 and 0.045, respectively). We also found that the g.-1514T>C and c.2103A>C polymorphisms of the TBX21 gene in the male RA patients have significant association with the levels of anti-CCP (P = 0.05) and rheumatoid factor (P = 0.03), respectively. These results suggest that the polymorphisms of the TBX21 gene might be associated with the susceptibility to male RA patients.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Alleles , Arthritis, Rheumatoid/genetics , Asian People/genetics , Genotype , Peptides, Cyclic/analysis , Polymorphism, Single Nucleotide , Rheumatoid Factor/analysis , Sex Factors , T-Box Domain Proteins/genetics , Th1 Cells/cytologyABSTRACT
Cyanobacterial blooms and associated microcystins in hypertrophic stagnant West-Nakdong River were investigated at weekly intervals from April to August, 1999. Microcystis spp. accounted for over 85% of the numeric abundance of total phytoplankton. Microcystins were present in the blooms sampled between May and August. The peak of total microcystin (microcystin-LR + -RR) levels (maximum level; 612 microg g(-1)) was detected in the initial stage of the bloom (mid May), at the same time as high N/P ratio and high Microcystis biomass. This study indicated that total microcystins of this regulated river was positively correlated to Microcystis biomass, absolute nutrient concentration and TN/TP ratio.